TheraRadar
← Back
Data updated: Sep 20, 2026

AFT PHARMACEUTICALS LTD

Pharma
Pharmaceuticals Execution: Fair

AFT PHARMACEUTICALS LTD is a pharmaceutical company with 1 FDA-approved products.

-
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

AFT PHARMACEUTICALS LTD at a Glance

  • Fast trial execution (12 months median completion)

AFT PHARMACEUTICALS LTD's Key Drugs

AFT PHARMACEUTICALS LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

AFT PHARMACEUTICALS LTD's Recent FDA Approvals

New NDA/BLA approvals for AFT PHARMACEUTICALS LTD over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AFT PHARMACEUTICALS LTD's Therapeutic Areas

Disease areas where AFT PHARMACEUTICALS LTD has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

AFT PHARMACEUTICALS LTD Pipeline Snapshot

Active clinical trials for AFT PHARMACEUTICALS LTD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Phase 3 Readout Calendar Pro

2 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2026
Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion)
Acute Pain
Estimated · aging NCT07225634
Q4 2026
Combogesic® tablets
Post Operative Pain, Acute
Estimated · aging NCT07225140

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • 2 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 3/5 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges